Treatments for Diffuse Large B-cell Lymphoma in Elderly Patients
the Cancer Therapy Advisor take:
Patients older than 80 are less likely to receive the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as treatment for diffuse large B-cell lymphoma (DLBCL), according to an article published online in Cancer.
Data was provided from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Characterization was complete according to presentation, treatment, and survival patterns in patients diagnosed with DLBCL between 2002 and 2009.
Of the 4,635 patients included, 1,156 (25%) were older than 80. Instead of receiving R-CHOP, the patients over 80 years were more likely to be observed or receive the combination of rituximab, cyclophosphamide, vincristine, and prednisone (P<0.0001 for both).
Through multivariable Cox proportional hazards models, the R-CHOP therapy regimen was determined to be the only regimen associated with improved overall survival (hazard ratio, 0.45; 95% confidence interval: 0.33-0.62) and lymphoma-related survival (hazard ratio, 0.58; 95% confidence interval: 0.38-0.88).
The study suggests that R-CHOP be considered as a regimen for patients older than 80 years and further studies be conducted on the correlation of treatment of DLBCL and the quality of life of these patients.
Elderly patients less likely to receive combination R-CHOP for lymphoma.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC